Product
anlotinib+TQB2450+nab-paclitaxel+cisplatin
1 clinical trial
1 indication
Indication
Biliary Tract CancerClinical trial
The Efficacy and Safety of Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2023-10-10